SCHEMBL1720006

SCHEMBL1720006

N#Cc1nccnc1Sc1nnc(SCc2ccccc2)s1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.47
HPGD P15428 2/20 0.47
FFAR1 O14842 1/20 0.46
MAPK1 P28482 1/20 0.46
TSHR P16473 2/20 0.46
ALDH1A1 P00352 4/20 0.45
MAPT P10636 2/20 0.45
SMN1; SMN2 Q16637 4/20 0.43
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
GAA P10253 3/20 0.41
PKM P14618 1/20 0.41
CA1 P00915 1/20 0.40
TERT O14746 1/20 0.39
DCUN1D1 Q96GG9 2/20 0.39
HSD17B10 Q99714 1/20 0.38
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6987084 0.81 LMNA (0.50) LMNAHPGDFFAR1MAPK1TSHR
SCHEMBL1719815 0.80 ALDH1A1 (0.39) LMNAHPGDMAPK1TSHRALDH1A1
SCHEMBL1720086 0.78 SMN1; SMN2 (0.40) LMNAHPGDMAPK1TSHRALDH1A1
SCHEMBL24700466 0.78 LMNA (0.66) LMNAHPGDFFAR1MAPK1TSHR
SCHEMBL1719852 0.77 TSHR (0.35) HPGDTSHRALDH1A1MAPTSMN1; SMN2
SCHEMBL1719384 0.77 KMT2A (0.35) ALDH1A1SMN1; SMN2MEN1KMT2ANPC1
SCHEMBL1719387 0.76 ALDH1A1 (0.40) LMNAHPGDMAPK1TSHRALDH1A1
SCHEMBL3263155 0.76 LMNA (0.72) LMNAHPGDFFAR1MAPK1TSHR
SCHEMBL1719442 0.76 MAPT (0.30) MAPTKMT2A
SCHEMBL1719407 0.75 ALDH1A1 (0.45) LMNAHPGDMAPK1TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130273024-A1 METHODS FOR TREATING ATHEROSCLEROSIS AMGEN INC (US) 2013-10-17 US claimed
EP-2452683-A2 Methods for treating atherosclerosis Amgen Inc. (US) 2012-05-16 EP claimed
EP-2037928-B1 METHODS FOR TREATING ATHEROSCLEROSIS AMGEN INC (US) 2012-01-11 EP claimed
EP-2037928-A2 METHODS FOR TREATING ATHEROSCLEROSIS Amgen Inc. (US) 2009-03-25 EP claimed
US-20080096900-A1 Methods for treating atherosclerosis AMGEN INC. (US) 2008-04-24 US claimed
WO-2008002591-A2 METHODS FOR TREATING ATHEROSCLEROSIS AMGEN INC (US) 2008-01-03 WO claimed
US-20130273024-A1 METHODS FOR TREATING ATHEROSCLEROSIS AMGEN INC (US) 2013-10-17 US disclosed
US-20130273024-A1 METHODS FOR TREATING ATHEROSCLEROSIS AMGEN INC (US) 2013-10-17 US disclosed
US-20130273024-A1 METHODS FOR TREATING ATHEROSCLEROSIS AMGEN INC (US) 2013-10-17 US disclosed
US-8426358-B2 Methods for treating atherosclerosis AMGEN INC. (US) 2013-04-23 US disclosed
US-8426358-B2 Methods for treating atherosclerosis AMGEN INC. (US) 2013-04-23 US disclosed
US-8426358-B2 Methods for treating atherosclerosis AMGEN INC. (US) 2013-04-23 US disclosed
EP-2452683-A2 Methods for treating atherosclerosis Amgen Inc. (US) 2012-05-16 EP disclosed
US-20110206652-A1 METHODS FOR TREATING ATHEROSCLEROSIS AMGEN INC. (US) 2011-08-25 US disclosed
US-20110206652-A1 METHODS FOR TREATING ATHEROSCLEROSIS AMGEN INC. (US) 2011-08-25 US disclosed
EP-2037928-A2 METHODS FOR TREATING ATHEROSCLEROSIS Amgen Inc. (US) 2009-03-25 EP disclosed
US-20080096900-A1 Methods for treating atherosclerosis AMGEN INC. (US) 2008-04-24 US disclosed
US-20080096900-A1 Methods for treating atherosclerosis AMGEN INC. (US) 2008-04-24 US disclosed
US-20080096900-A1 Methods for treating atherosclerosis AMGEN INC. (US) 2008-04-24 US disclosed
WO-2008002591-A2 METHODS FOR TREATING ATHEROSCLEROSIS AMGEN INC (US) 2008-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130273024-A1 METHODS FOR TREATING ATHEROSCLEROSIS LCAT, PCSK9, CETP LMNA 535/4885HPGD 1390/4885FFAR1 894/4885
US-20080096900-A1 Methods for treating atherosclerosis LCAT, PCSK9, CETP LMNA 535/4885HPGD 1390/4885FFAR1 894/4885
US-20110206652-A1 METHODS FOR TREATING ATHEROSCLEROSIS LCAT, PCSK9, CETP LMNA 535/4885HPGD 1390/4885FFAR1 894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.